Table 1.

List of studies examining bisphosphonates in total joint arthroplasty.

Article	Type of study	Patients (n)	THA/TKA	Bisphosphonate used	Outcome measure
von Knoch et al. [18]	Preclinical	36	TKA	Alendronate/Zoledronic acid	Cortical thickness, bone volume, osteoid thickness
Mochida et al. [19]	Preclinical	24	THA	Alendronate	Early bony ingrowth
Li et al. [20]	Meta-analysis	275	THA	Risedronate	Bone mineral density, Harris hip score, bony resorption
Aro et al. [21]	Retrospective	51	THA	Zoledronic acid	Bone mineral density
Gao et al. [22]	Meta-analysis	185	THA	Zoledronic acid	Bone mineral density
Shi et al. [23]	Meta-analysis	1163	THA/TKA	All bisphosphonates	Bone mineral density
Wang et al. [24]	Prospective RCT	91 women	TKA	Alendronate	Bone mineral density
Bhandari et al. [25]	Retrospective	290	THA/TKA	All bisphosphonates	Bone mineral density
Namba et al. [26]	Meta-analysis	34,116	TKA	All bisphosphonates	Aseptic revision rate
Ro et al. [27]	Meta-analysis	56,043 THA 331,660 TKA	THA/TKA	All bisphosphonates	All-cause revision rate
Prieto-Alhambra et al. [28]	Case-control meta-analysis	10,524	THA/TKA	All bisphosphonates	All-cause revision rate
Yang [29]	Meta-analysis of RCTs	198	THA	Risedronate	Bone mineral density
Teng [30]	Meta-analysis	31,293	THA/TKA	All bisphosphonates	All-cause revision rate
Zhou et al. [31]	RCT	40	THA	Zoledronic acid	Bone mineral density
Khatod et al. [32]	Retrospective	12,878	THA	All bisphosphonates	All-cause revision, periprosthetic fracture

RCT, randomized controlled trial.